Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oxigene, a biopharmaceutical company, has reported positive data from the Falcon trial which assessed efficacy of Zybrestat (fosbretabulin tromethamine, or CA4P) in patients with advanced non-small cell lung cancer (NSCLC).
Subscribe to our email newsletter
Zybrestat selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells.
Falcon is a randomized, controlled Phase 2 study investigating the addition of Zybrestat to standard therapy (carboplatin, paclitaxel, and bevacizumab, or C/P/Bev) in patients with Stage IIIb or IV predominantly non-squamous NSCLC.
The data demonstrated that the combination regimen of Zybrestat plus bevacizumab, carboplatin and paclitaxel (Zybrestat arm) was well-tolerated when compared with the control arm of the study (standard chemotherapy plus bevacizumab).
Moreover, patients with tumor burden greater than 10 cm showed improvements in overall survival for patients receiving Zybrestat in addition to bevacizumab and chemotherapy.